Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
A variety of bacteria have been shown to enter and replicate within tumors, exhibiting "tumor finding" behavior. In addition, the bacteria themselves have a variety of elements that activate toll-like receptors. Alfa Cytology provides high-quality bacteria-based delivery system development services to help our clients with cancer vaccine development.
Live, attenuated, or genetically modified obligate or facultative anaerobic bacterial species exhibit the inherent property of colonizing tumors and can selectively multiply within tumors, thereby inhibiting cancerous growth. While there are multiple implications for cancer treatment, care needs to be taken to consider biosafety, genetic instability, and complex interactions between bacteria and therapeutic agents. Here are some of the advantages of bacteria-based delivery systems.
Bacterial vectors display the ability to carry, make, and deliver anticancer agents in the form of drugs, therapeutic DNA, microRNA, shRNA, siRNA, cytotoxic agents, antiangiogenic agents, and specific enzymes that convert prodrugs into anticancer drugs. Targeting different customer needs, Alfa Cytology provides diversified bacteria-based delivery systems development services, including but not limited to the following.
Bacterial Outer Membrane Vesicles Delivery Systems Development Service
Bacterial outer membrane vesicles (OMV) are a kind of double-membrane vesicles secreted by Gram-negative bacteria during their growth and life, and play an extremely important role in the survival and invasion of bacteria. In particular, OMV contains a large number of immunogenic components associated with its parent bacteria and can be used as vaccines, adjuvants and carriers to treat diseases, especially in the presentation of tumor antigens or small molecule drug targeted therapies.
Bacillus-based Delivery Systems Development Service
Inspired by the effective immune response against microorganisms, demi-bacteria (DB) from Bacillus were designed as vectors for cancer vaccines. Hydrothermal treatment enables Bacillus to effectively accommodate antigens and adjuvants. Thus, this optimized engineered nanostructure allows multiple immune-stimulating elements to be integrated, in a very similar pattern to bacterial pathogens. This pathogen mimicry greatly enhances antigen uptake and cross-presentation, resulting in stronger immune activation suitable for cancer vaccines.
S. Typhimurium-based Delivery Systems Development Service
One advantage of using attenuated or inactivated Salmonella typhimurium as a therapeutic cancer vaccine is that it can stimulate humoral and cellular system immune responses as well as mucosal immune responses. In particular, engineered Salmonella typhimurium retain complete epitopes and are less toxic.
We have extensive experience in the field of cancer vaccine development.
We have advanced laboratory facilities and technology platforms.
We can provide customized solutions based on specific customer needs and project objectives.
We are committed to providing high-quality research results and reliable data support.
Genetically engineered bacteria are widely used in cancer vaccines Alfa Cytology is committed to developing all kinds of cancer vaccine delivery systems and has in-depth and extensive preclinical experience. If you are interested in our service, please feel free to contact us for more details.